Safety of L1-79 in Adolescent and Adult Males With Autism

计划入组 42 人 · 首次发布于 2016 年 10 月 27 日

A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

计划入组 58 人 · 首次发布于 2021 年 10 月 5 日

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

计划入组 27 人 · 首次发布于 2008 年 3 月 6 日

HLX-79

AUR-79

RTI-79

Xi'an No.4 Hospital

China

Guiyang No.4 People's Hospital

China

Huai'an No.4 People's Hospital

China

Supercede Therapeutics Reports Promising Preclinical Data for Novel Oral Obesity Treatment Targeting ACTRII Pathway

Tezepelumab Shows 79% Reduction in Severe Asthma Exacerbations in Real-World Study

Yamo Pharmaceuticals Reports Breakthrough Phase 2 Results for Novel Autism Treatment L1-79